Mineralys Therapeutics (MLYS) Prepaid Assets (2022 - 2026)
Mineralys Therapeutics' (MLYS) quarterly Prepaid Assets came in at $6.4 million in Q1 2026, down 44.16% year-on-year from $11.5 million in Q1 2025, and up 34.92% quarter-over-quarter from $4.8 million in Q4 2025.
Mineralys Therapeutics (MLYS) Prepaid Assets (2022 - 2026) Analysis & Trends
Mineralys Therapeutics has disclosed Prepaid Assets across 5 years of filings, most recently posting $6.4 million for Q1 2026.
- Prepaid Assets for Q1 2026 came in at $6.4 million, down 44.16% year-over-year; the trailing twelve-month figure through Mar 2026 was $6.4 million (down 44.16% YoY), and the FY2025 annual result was $4.8 million, down 33.68% from the prior year.
- Prepaid Assets came in at $6.4 million for Q1 2026 at Mineralys Therapeutics, up from $4.8 million in the prior quarter.
- In the past five years, Prepaid Assets ranged from a high of $12.5 million in Q4 2023 to a low of $2.7 million in Q4 2022.
- The 5-year median for Prepaid Assets is $7.0 million (2024), against an average of $7.5 million.
- Across the five-year window, Prepaid Assets jumped 364.12% in 2023 and slumped 64.45% in 2024, its largest moves.
- Mineralys Therapeutics' Prepaid Assets stood at $2.7 million in 2022, then surged by 364.12% to $12.5 million in 2023, then tumbled by 42.85% to $7.2 million in 2024, then sank by 33.68% to $4.8 million in 2025, then jumped by 34.92% to $6.4 million in 2026.
- The last three Prepaid Assets figures came in at $6.4 million (Q1 2026), $4.8 million (Q4 2025), and $6.2 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 814,307.08 Bn | 814,307.05 Bn | - |
| 2 | Belite Bio | 55,320.00 Bn | 55,320.00 Bn | - |
| 3 | Quantum Biopharma | 17,149.72 Bn | 17,149.72 Bn | - |
| 4 | Legend Biotech | 3,590.00 Bn | 3,589.71 Bn | 242.10 Mn |
| 5 | Akari Therapeutics | 1,650.72 Bn | 1,650.72 Bn | - |
| 6 | Evaxion A | 1,522.09 Bn | 1,522.07 Bn | - |
| 7 | Psyence Biomedical | 229.39 Bn | 229.38 Bn | - |
| 8 | Vertex Pharmaceuticals | 113.09 Bn | 105.85 Bn | 2.59 Bn |
| 9 | Abivax | 90.15 Bn | 90.15 Bn | - |
| 10 | Mineralys Therapeutics | 1.95 Bn | 1.95 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 6.41 Mn |
| Dec 31, 2025 | 4.75 Mn |
| Sep 30, 2025 | 6.17 Mn |
| Jun 30, 2025 | 10.35 Mn |
| Mar 31, 2025 | 11.48 Mn |
| Dec 31, 2024 | 7.16 Mn |
| Sep 30, 2024 | 4.13 Mn |
| Jun 30, 2024 | 6.89 Mn |
| Mar 31, 2024 | 8.25 Mn |
| Dec 31, 2023 | 12.54 Mn |
| Sep 30, 2023 | 11.61 Mn |
| Jun 30, 2023 | 8.39 Mn |
| Mar 31, 2023 | 4.64 Mn |
| Dec 31, 2022 | 2.70 Mn |